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CD4+Foxp3+ regulatory T cells (Treg cells) are known
to control the progression of autoimmune diabetes,
but when, where, and how they exert their influence
in this context are questions still under vigorous
debate. Exploiting a transgene encoding the human
diphtheria toxin receptor, we punctually and specifi-
cally ablated Foxp3+ cells in the BCD2.5/NODmouse
model of autoimmune diabetes. Strikingly, overt dis-
ease developed within 3 days. The earliest detect-
able event was the activation of natural killer (NK)
cells directly within the insulitic lesion, particularly
the induction of Ifng gene expression within 7 hours
of Treg cell ablation. Interferon-g had a strong impact
on the gene-expression program of the local
CD4+ T effector cell population, unleashing it to
aggressively attack the islets, which was required
for the development of diabetes. Thus, Treg cells
regulate pancreatic autoimmunity in situ through
control of a central innate immune system player,
NK cells.
INTRODUCTION
Foxp3+CD4+ regulatory T (Treg) cells regulate a variety of
immune responses, including autoimmunity, allergy, inflamma-
tion, infection, and tumorigenesis (Zheng and Rudensky, 2007;
Sakaguchi et al., 2008). This cell population is required life-long
to guard against autoimmunity, perhaps best illustrated by the
multiorgan infiltrates that arise a few weeks after its acute abla-
tion in adult mice (Kim et al., 2007). In particular, Treg cells play
a crucial role in protection from type-1 diabetes (T1D), an auto-
immune disease characterized by specific attack of the insulin-
producing b cells of the pancreatic islets (Tang and Bluestone,
2008). For example, autoimmune diabetes is one of the major
elements of the IPEX (immune dysfunction, polyendocrinopathy,
entreropathy, X-linked inheritance) syndrome that afflicts654 Immunity 31, 654–664, October 16, 2009 ª2009 Elsevier Inc.humanswith adefective Treg cell compartment due to amutation
in the FOXP3 gene (Bennett et al., 2001; Wildin et al., 2001).
Moreover, transfer of Treg cells can protect mice from autoim-
mune diabetes, whether in the NOD model or in T cell receptor
(TCR) transgenic systems derived thereof (Salomon et al.,
2000; Tarbell et al., 2004; Tang et al., 2004; Herman et al.,
2004; Tarbell et al., 2007). Conversely, genetic deficiencies or
experimental manipulations that reduce numbers or activity of
this regulatory population can exacerbate diabetes (Salomon
et al., 2000; Chen et al., 2005).
The precise point at which Treg cells impact on the behavior of
effector T (Teff) cells to rein in autoimmunity, and the pathways
involved, remain controversial issues (Zheng and Rudensky,
2007; Sakaguchi et al., 2008). Several junctures are possible
and have been highlighted in different experimental settings:
the migration of naive T cells to the lymph nodes (LNs) draining
the target tissue(s); their activation, expansion, or survival
therein; differentiation to a particular T helper (Th) cell phenotype;
homing of activated Teff cells to target tissues; their expansion or
survival after arrival; and their ultimate destructiveness toward
the tissues.
Concerning diabetes, several groups have focused on Treg cell
influences at an early stage—initial priming of potentially diabeto-
genic T cells within the pancreatic LNs (PLNs). Proliferation of
islet-reactive BDC2.5 Teff cells in the PLNs was inhibited by pre-
administration of a large number of Treg cells and, conversely,
was enhanced when BDC2.5 effectors were transferred into
Treg-cell-deficient Cd28/ mice (Tang et al., 2006), consistent
with previously published results issuing from related experi-
mental manipulations (Bour-Jordan et al., 2004). In other cases,
although Treg cells did not inhibit the expansion of islet-reactive
Teff cells within the PLNs, they did impede their early differentia-
tion at that site, reducing the production of IFN-g and expression
of chemokine receptors (such as CXCR3) needed formigration to
the islets (Sarweenetal., 2004) ordiminishing the fractionofTcells
producing tumor necrosis factor (TNF)-aor interleukin (IL)-17 (Tritt
et al., 2008). Effects on the survival of differentiated Teff cells
within the PLNs have also been postulated (Tritt et al., 2008).
On the other hand, such influences of Treg cells on the priming
phase of islet-reactive T cells were not evident in several other
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erate equivalently in their presence or absence (e.g., Chen et al.,
2005). Despite some initial technical difficulties in finding them, it
is now clear that Treg cells are prominent residents of many
types of autoimmune tissular infiltrates, both murine and human
(Zheng and Rudensky, 2007; Sakaguchi et al., 2008). Some
investigators have argued that they are inoperative in such an
inflammatory context, given that tissue damage eventually
occurs (e.g., Korn et al., 2007), but this conclusion ignores the
fact that destruction might have been worse in their absence.
Treg cells are readily found in prediabetic islet infiltrates, where
they have a distinct phenotype, prompting us to propose that
such tissue-resident regulatory cells are a key element in local
immunoregulation, capable of staving off the terminal destruc-
tion of islet b cells for a protracted period (Chen et al., 2005;
Herman et al., 2004).
Some of the discrepancies highlighted above no doubt issue
from the experimental strategies chosen in the different studies.
Transfer systems, employed inmost of the experiments, may not
mimic the natural disease course, especially when they entail
lymphopenic mice as T cell recipients. Chen et al. (2005) tried
to sidestep this issue by introducing the scurfy (Foxp3-defi-
ciency) mutation into the BDC2.5 TCR transgenic diabetes
model, but it is possible that immune system adaptation takes
place in the constitutive absence of Treg cells. We have now ad-
dressed this issue using a more definitive approach: BAC trans-
genic mice expressing the diphtheria toxin (DT) receptor (R)
under the dictates of Foxp3 transcriptional regulatory elements
were generated directly on the NOD genetic background, allow-
ing temporally controlled ablation specifically of Treg cells.
Exploiting this new resource, we have assessed where and
how Treg cells impact on the anti-islet autoimmune response.
The strength and synchrony of the rapidly ensuing reaction
were instrumental in elucidating the pathway by which Treg cells
keep the immune system at bay. In particular, it became feasible
to study how Treg cells dampen effector cells within the insulitic
lesion to stave off the conversion of insulitis to diabetes, a thera-
peutically critical disease juncture. Unexpectedly, an effect of
Treg cells on innate immune system players, notably NK cells,
appears to be an early and crucial event.
RESULTS
An Ongoing Need for Treg Cells to Guard against
Autoimmune Destruction of the Pancreatic Islets
Controlled lineage ablation is a powerful approach for deter-
mining the role of particular cell types in specialized biological
processes. More and more, transgene-directed expression of
the human DTR in particular cells in mice is being exploited to
achieve this goal: murine cells are resistant to DT for lack of
a receptor, so those expressing the DTR transgene are uniquely
sensitive to DT treatment in vivo (Saito et al., 2001). Importantly,
since the death induced by this drug is apoptotic, cell ablation
has not provoked an inflammatory response in the many
contexts so far examined (Bennett and Clausen, 2007; Feuerer
et al., 2009). Recently, this strategy was successfully employed
to selectively eliminate Treg cells in mice (Kim et al., 2007; Lahl
et al., 2007; Lund et al., 2008).We generated a Foxp3-DTR line directly on the NOD genetic
background by injecting NOD embryos with a large BAC
construct harboring a chimeric DTR-eGFP-stop coding segment
inserted between the first and second codons of the Foxp3 open
reading frame (Figure S1A available online). Multiple founders
expressing GFP in CD4+CD25+ T cells were obtained, one of
which was used to propagate a stable line (NOD.Foxp3DTR+).
Two consecutive daily administrations of DT into young adults
of this line resulted in an 80%–90% depletion of the Foxp3+
T cells in lymphoid organs such as the spleen, axillary LN, and
PLN (data not shown, but see below). By 3 days after the last
injection, Treg cell numbers had recovered to a substantial
degree (to only 60% depletion) (data not shown). On one
hand, if DT was administered to young adults every other day
until day 9 and histological analysis was performed on day 12,
only very mild infiltrates were detected in the lung and liver of
Foxp3-DTR transgenicmice (but not of transgene-negative litter-
mate control animals) (Figure S1B). On the other hand, the
pancreatic islets of the DT-injected transgenic mice showed
a strong immune infiltrate at that time-point after treatment, in
contrast to the identically treated littermate controls.
The goal of this study was to elucidate the role of Treg cells in
controlling the progression of autoimmune diabetes. To that end,
we crossed the Foxp3-DTR transgene into the BDC2.5 TCR
transgenic mouse model. The BDC2.5 line derives from a CD4+
T cell clone that is restricted by the NODMHC-class-II Ag7 mole-
cule and is specific for an unknown pancreatic islet b-cell
protein (Katz et al., 1993; Haskins et al., 1988). This line has
been instrumental in elucidating the constellation of immunoreg-
ulatory genes, molecules, and cells that control the frequency
and aggressivity of diabetogenic T cells (Gonzalez et al., 1997;
Luhder et al., 1998; Kanagawa et al., 2002; Poirot et al., 2004).
In BDC2.5 mice, T cells invade the islets at 15–18 days of age
and seed a massive infiltration therein; however, on the NOD
genetic background, progression to diabetes occurs only
months later in only 10%–20% of animals, reflecting strong
immunoregulation at play. Thus, this model has the attractions
of being well studied, having a T cell compartment that can be
easily tracked, being conveniently synchronous, and exhibiting
readily discernable immunoregulation.
BDC2.5/NOD.Foxp3DTR+ double-transgenic mice showed an
efficiency of Treg cell depletion, including ablation of the popula-
tion residing in the pancreas, similar to that mentioned above for
the polyclonal NOD.Foxp3DTR+ animals (Figure 1A). In a first set
of experiments, the double-transgenic mice were assessed 24,
72, and 120 hr after the depletion of Treg cells. As documented
in Figure 1B, histological changes could be observed as early as
the 24 hr time point. The innocuous, static-looking infiltrate char-
acteristic of negative-control mice had begun to evolve such that
the leukocyte mass seemed to breach its boundaries and infil-
trate deeply into the islet space. In addition, the border between
the endocrine and exocrine tissue became much more fuzzy
(second row of panels, arrowhead). After 72 hr, the leukocytes
appeared to aggressively swarm throughout the islets, even
beginning to invade the exocrine pancreas (third row, arrow-
head). During the next 2 days, the islet completely disaggre-
gated, making it difficult to recognize b cells, and the infiltrate
escaped massively into the exocrine tissue (bottom row, arrow-
head). This picture is very reminiscent of what we previouslyImmunity 31, 654–664, October 16, 2009 ª2009 Elsevier Inc. 655
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Figure 1. Kinetics of the Autoimmune
Attack on the Pancreas
(A) NOD.Foxp3DTR+ mice were crossed with
BDC2.5 TCR tg mice (Katz et al., 1993), and Treg
cell depletion was analyzed. Percentage of Treg
cells after two daily injections of DT into BDC2.5/
NOD.Foxp3DTR+ and DTR control littermates is
shown. Representative dot plots for axillary LN
(axLN), PLN, and pancreas tissue are shown.
(B and C) DT injections into 4- to 5-week-old
BDC2.5/NOD.Foxp3DTR+ mice induced a rapid
onset of diabetes. (B) Histological sections of
pancreas tissue after H&E staining, with two
different magnifications of the same area: 103
objective left column and 203 objective right
column. (B, upper panel) BDC2.5/NOD.Foxp3DTR
control animal 120 hr after DT treatment. (B, middle
and lower panels) BDC2.5/NOD.Foxp3DTR+ mice
analyzed at different time points after DT treat-
ment: 24 hr, 72 hr, and 120 hr. Arrowheads indicate
text-cited areas of infiltration. Representative
sections are shown. (C) Diabetes incidence of
BDC2.5/NOD.Foxp3DTR+ (n = 9) and DTR-negative
control littermates (n = 9) after DT treatment as
described in Experimental Procedures. Arrows
indicate days of DT injection.documented for Foxp3-defective and Rag-deficient BDC2.5
TCR transgenic mice (Chen et al., 2005).
In agreement with these findings, diabetes occurred as soon
as 3–5 days after the punctual ablation of Treg cells from adult
BDC2.5/NOD.Foxp3DTR+ mice (Figure 1C), clearly demon-
strating an ongoing need for Treg cells to guard against autoim-
mune attack of the pancreas.
The Removal of Treg Cells Activates Teff Cells
Predominately within the Pancreas
Given the strength and synchrony of the disease that rapidly
developed subsequent to Treg cell depletion, this system
seemed a highly advantageous one for elucidating how Treg
cells rein in Teff cells in the T1D context. First, we asked where
Treg cells were having the greatest effects: in the PLNs, the
site of ongoing T cell priming, or within the insulitic lesion itself?
We initially employed microarray gene-expression profiling as
a broad, unbiased approach to addressing this question,
focusing on CD4+ T cells because they are the primary effector
cells in the BDC2.5 model. Non-Treg T cells were sorted as
GFP-negative at 0, 15, and 24 hr after a single injection of
BDC2.5/NOD.Foxp3DTR+ mice and BDC2.5/NOD.Foxp3DTR
littermate controls with DT. RNA samples were prepared in trip-
licate and were hybridized to Affymetrix M430v2 microarrays,
and RNA-normalized expression values were analyzed. (Data-
sets have been deposited at NCBI-GEO under accession no.
GSE18136.)
A global comparison of gene-expression values revealed that
far more extensive changes occurred in the pancreas-derived
CD4+ Teff cells than in their PLN counterparts: at an arbitrary
counting threshold of 2-fold changes, 352 genes were overex-
pressed in the pancreas 24 hr after Treg cell ablation, while
168 genes were underrepresented, versus 46 and 26, respec-
tively, in the PLN (Figure 2A, left panels; Table S1). A direct656 Immunity 31, 654–664, October 16, 2009 ª2009 Elsevier Inc.comparison of transcript alterations in a fold change-fold change
(FC-FC) plot demonstrated that many of the same changes
occurred in the pancreas and the PLNs, but the off-diagonal
alignment (slope = 0.36) confirmed the dominant pancreas
response (Figure 2B, left panel). At 15 hr, CD4+ Teff cells from
both sites exhibited only minor alterations in gene expression
(Figures 2A and 2B, right panels); however, highlighting on the
15 hr plots those genes whose expression had changed by
24 hr revealed that the response was already beginning at the
earlier time point for certain loci, with a bias for both overex-
pressed (in red) and underrepresented (in blue) genes (Fig-
ure 2C). Thus, elimination of Treg cells had a dominant impact
within the insulitic lesion, rather than in the draining lymph nodes,
and the response was surprisingly rapid, discernible by as few as
10–12 hr or so (considering that the death of Treg cells in
response to DT must take at least a few hours).
To begin characterizing the effects on Teff cells, we high-
lighted on the FC-FC plot of Figure 2D a T cell activation-prolif-
eration signature previously defined on the basis of compiled
analyses of T cells stimulated by antigen in vitro or in vivo (Hill
et al., 2007). At 24 hr after Treg cell depletion, transcripts of
the activation-proliferation signature were clearly altered in the
pancreas, but far less so in the PLN. There was little to no change
in this signature at 15 hr. For an independent verification of these
conclusions, we isolated CD4+ T cells from the pancreas and
PLN at 15, 20, and 24 hr after Treg cell removal and analyzed
them by flow cytometry for expression of the early activation
marker CD69 (Figure 2E). Pancreas-resident CD4+ T cells
showed an increase in cell-surface display of CD69 between
15 and 20 hr, consistent with the gene-expression profile. As
expected, PLN-derived CD4+ T cells did not exhibit a significant
change in CD69 expression at these early time points.
Because the highlighted signature included proliferation-
associated transcripts, we confirmed the above conclusions in
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Figure 2. T Cell Activation and Proliferation in the Pancreatic Lesion
(A–D) Affymetrix M430 2.0 microarray data. CD4+ T cells were isolated from the pancreas lesion and PLN at three different time points: 0, 15, and 24 hr after DT
treatment fromBDC2.5/NOD.Foxp3DTR+mice. (A) Expression versus expression values are plotted for pancreas and PLN at 24 and 15 hr. Numbers indicate count
of probes that were differentially expressed more than 2-fold. (B–D) Fold change to fold-change plot. (B) 24 hr versus 0 hr for PLN and pancreas (left panel) and
15 hr versus 0 hr for PLN and pancreas (right panel). Red line (in left panel) represents the linear regression curve. (C) Gene changes after 24 hr (and presented in
Table S1) are highlighted in the 15 hr versus 0 hr PLN versus pancreas plot (left panel) and random data control (right panel). (D) Activation and proliferation
responsive genes (Hill et al., 2007) overexpressed (red) or underrepresented (blue) are highlighted in 24 hr versus 0 hr for PLN and pancreas (left panel) and
15 hr versus 0 hr for PLN and pancreas (right panel).
(E) CD4+ T cells were stained for the early activation marker CD69 at different time points after DT treatment from pancreas and PLN, from BDC2.5/NOD.
Foxp3DTR+ (filled symbols) and BDC2.5/NOD.Foxp3DTR control mice (open symbols).
(F) BrdU staining of CD4+ T eff cells: BrdU was injected 48 hr after DT treatment and mice were analyzed after 1 hour. Pancreas and PLN from BDC2.5/NOD.
Foxp3DTR+ or DTR-negative control mice were stained for BrdU and CD4. Left panel shows representative dot plots, right panel summarizes four to five mice
from independent experiments with mean and SD. *Significant difference (p < 0.05).bromodeoxyuridine (BrdU)-labeling experiments. Mice were
intravenously (i.v.) injected with BrdU 48 hr after DT administra-
tion, the pancreas and PLN were excised 1 hour later, and cells
were stained for incorporation of BrdU into their DNA as an indi-
cator of proliferation. We chose this very early time point to
exclude the possibility of division elsewhere followed by labeled
cell migration into the pancreas. Again, pancreas-resident CD4+
T cells showed a substantial early reaction: about 13%were in S
phase during the labeling period, compared with only about 2%
in the DT-treated DTR-negative littermate control group
(Figure 2F). In contrast, the division of PLN-derived CD4+
T cells was not significantly different from that of their negative
control counterparts. The dichotomy in proliferation was also
seen with CD8+ T cells from the pancreas versus PLN, with
high rates in the former and less increase in the latter (Figure S2).
By these diverse criteria, then, Treg cell ablation can unleash
a rapid activation of CD4+ Teff cells residing within the autoim-
mune lesion while not in the draining LNs.The CD4+ Teff Cell Response Unleashed by Treg Cell
Depletion
Thus, Treg cells restrain Teff cells within the insulitic lesion, inhib-
iting terminal destruction of the mass of b cells. But what are the
critical effector functions thereby kept in check? And what mole-
cules drive these functions? Many of the genes highly induced in
response to Treg cell ablation are implicated in the function of
known Th subsets, notably transcripts encoding Tbet (3.8-fold
overexpressed), IL-12rb1 (2.3-fold), IFN-g (9.9-fold), granzyme
B (6.1-fold), and granzyme A (2.6-fold) for Th1 cells and IL-17
(2.3-fold), IL-22 (9.3-fold), and IL-21 (3.7-fold) for Th17 cells
(Figure 3A and Table S1). A number of these alterations were
confirmed by flow-cytometric or quantitative-PCR analysis. For
example, monoclonal antibody (mAb) staining for intracellular
IFN-g and IL-17 showed an increase in pancreas Teff cells at
48 hr after Treg cell depletion, and also an augmentation in
IFN-g production in PLN cells at this later time point (Figures
3B and 3C). In contrast, there were no evident differences inImmunity 31, 654–664, October 16, 2009 ª2009 Elsevier Inc. 657
Immunity
Treg Cell Control of an Insulitic Lesionthe intracellular expression of TNF-a, IL-4, IL-10, and IL-2 in
pancreas Teff cells (Figure S3).
We wondered whether IFN-g might be an important ‘‘driver’’
cytokine because (1) transcripts encoding Tbet, which induces
this cytokine’s expression, were upregulated in pancreas CD4+
Teff cells already at 15 hr after Treg cell ablation (Table S1); (2)
transcripts encoding IFN-g, itself, though not yet induced in
this population at 15 hr, were strongly upregulated by 24 hr
(Table S1), and more of the cells were actually producing this
cytokine (Figure 3B); and (3) isolated BDC.2.5 Th1 cells rapidly
provoke autoimmune diabetes upon transfer (Katz et al., 1995).
Thus, we overlaid an IFN-g-response signature (independently
derived [J. Wu, D.M., C.B., unpublished data]) onto the p value
versus FC ‘‘volcano’’ plots of the CD4+ T cell expression
values. A clear displacement of the IFN-g-induced (red) and
IFN-g-repressed (blue) transcripts was already evident at 15 hr
(Figures 4Ai and 4Aii; p = 4.8516). A control TGF-b signature
showed no such bias—if anything, the TGF-b-induced tran-
scripts were slightly underrepresented (Figures 4Aiii and 4Aiv).
Subsequent to Treg cell ablation, IFN-g-responsive genes
were upregulated in CD4+ Teff cells faster than the genes of
the activation signature were and faster than the Ifng gene itself
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Figure 3. Molecular Changes after Treg Cell Ablation
(A) Microarray data showing fold change versus expression value plot for 24 hr
versus 0 hr (left panel) and 15 hr versus 0 hr (right panel) for T cells isolated from
the pancreas. Some overexpressed genes are highlighted.
(B and C) Cytokine expression of CD4+ T cells from pancreas and PLN, 48 hr
after DT injection into BDC2.5/NOD.Foxp3DTR+ or DTR-negative control mice.
(B), IFN-g; (C), IL-17. Upper panel, dot plots; lower panel, summary of four
mice per group with mean + SD. *Significant difference (p < 0.05).658 Immunity 31, 654–664, October 16, 2009 ª2009 Elsevier Inc.was (Figure 4B, upper and lower panels), prompting us to search
for other cells producing this cytokine. We performed a careful
kinetic analysis around this early time point, quantifying IFN-g
transcript levels in CD4+, CD8+, andNK cells from various organs
(Figure 4C). All cell types from all organs of the DT-treated DTR-
negative littermate controls showed background levels of IFN-g
transcripts at all of the time points. Unexpectedly, NK cells
exhibited the earliest, greatest response. There was a burst of
Ifng expression by NK cells from the insulitic lesion as soon as
15 hr after DT injection, which was barely detectable in the
PLN NK cells and was undetectable in the spleen NK population.
In clear contrast, IFN-g transcripts were not upregulated in either
CD4+ or CD8+ cells at this time point, but only after a lag of about
9 hr, though only in the lesion and never reaching the expression
in NK cells.
NK Cells Sense the Loss of Treg Cell Control
Thestriking induction of IFN-gexpressionbyNKcells in response
to declining Treg cell numbers suggested that this innate immune
system cell type might play a primordial role in diabetogenesis in
this setting. We first addressed this possibility by analyzing the
percentage, proliferation, and effector molecule expression of
NK cells in the PLN and pancreas during the course of Treg cell
ablation. The percentage of NK cells in the pancreas steadily
increased along with the decrease in Treg cells, rising from about
2% to about 10%by 48 hr, with the first significant augmentation
(p = 0.048) occurring between 15 and 20 hr after the initial admin-
istration of DT (Figure 5A, upper and lower panels). The rise in NK
cells in the PLN was more moderate and lagged somewhat
behind, a substantial increase not being apparent until 48 hr (Fig-
ure 5A, lower panel). BrdU-labeling experiments at 48 hr revealed
NK cells in both the pancreas and PLN to be actively proliferating
(Figure 5B). Again, the short (1 hr) BrdUpulse argued that the bulk
of the BrdU labeling represented in situ proliferation rather than
an influx of cells that had divided elsewhere.
We wondered whether the induction of IFN-g synthesis by NK
cells was accompanied by an increase in the NK-cell killing poten-
tial as well. Indeed, PCR analysis at 24 hr after DT-injection did
show an augmentation in transcripts encoding granzymes A and
B, especially in the insulitic lesion, and less so in the PLN (Fig-
ure 5C). While Gzma mRNA was expressed essentially only in
NK cells, Gzmb transcripts were upregulated in pancreatic CD4+
and CD8+ T cells in addition (data not shown). An in vivo cytoxicity
assay confirmed the unleashing of NK cell activity upon Treg cell
ablation (Figure 5D). DTR-positive or DTR-negative BDC2.5/NOD
mice were depleted of Treg cells two days before injection of
a mix of splenocyte populations (CFSElo MHCI-negative targets
and CFSEhi MHCI-positive controls); sixteen hours later, NK cell
activity in different organs was measured by comparing the ratio
of the twopopulations.NKactivitywassignificantlyenhancedafter
Tregcell depletion, in thepancreatic tissue (p=0.017) anddraining
LN (p = 0.0058), and also in the spleen at this rather late time point.
These results provide important evidence that Treg cell ablation
impacts on NK cell activity itself and in an in vivo context.
The IFN-g Induction Triggered by a Loss of Treg Cells
Is Prodiabetogenic
We have shown, then, that specific, punctual depletion of Treg
cells provoked a rapid rise in NK cell production of IFN-g in
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Figure 4. Induction of IFN-g Expression Is
An Early, Predominant Response after
Punctual Treg Cell Depletion
(A) CD4+ T cells were isolated from the pancreas
at three different time points: 0, 15, and 24 hr after
DT treatment from BDC2.5/NOD.Foxp3DTR+
mice. (Ai–Aiv) p value versus fold change (FC)
‘‘volcano’’ plot for the pancreas CD4+ Teff popula-
tion at 24 and 15 hr after DT treatment. IFN-g-
responsive genes (Bi and Bii) or TGF-b-respon-
sive transcripts (Aiii and Aiv) either upregulated
(red) or downregulated (blue) by the respective
cytokine were highlighted. p values presented
within the graphs (Ai–Aiv) were calculated (c2
analysis) based on the number of genes dropping
to the left or right side of the FC distribution (colors
indicate upregulated [red] or downregulated [blue]
genes). Red or blue digits in the upper corner of
each plot indicate the number of probes on each
side of the distribution. (Ai) and (Aiii) at 24 hr; (Aii)
and (Aiv) at 15 hr.
(B) Upper panel: Log2 delta expression values of
(15 hr  0 hr) and (24 hr  0 hr) for genes from
three different signatures: IFN-g (red), activation/
proliferation (blue), and TGF-b (black). Lower
panel: IFN-g expression in CD4+ Teff cells isolated
from the pancreas at 0, 15, and 24 hr after DT.
(C) Quantitative PCR for IFN-g expression.
CD4+, NK, and CD8+ cells were isolated from
spleen, pancreas, and PLN from BDC2.5/NOD.
Foxp3DTR+ or DTR-negative control mice at
different time points (15, 20, and 24 hr) after DT
injection. Data are expressed as arbitrary units
(AU), and the mean + SD from four independent
experiments are shown.pancreas tissue targeted by autoimmunity, which in turn sub-
stantially impacts on the gene expression program of the
pancreas-resident CD4+ Teff cells. The implication is that
IFN-g is an important trigger of diabetogenesis in this context,
a notion we tested by performing mAb blocking studies. Anti-
IFN-g was administered coincident with the DT treatment, and
its effects were monitored 24 hr later. One consequence was
a substantial reduction in the augmentation of pancreatic NK
cells usually provoked by Treg cell ablation (Figure 6A). In addi-
tion, there were effects on the expression of effector genes in NK
and other cell populations. The induction of Ifng gene transcrip-
tion in NK cells, CD4+ T cells, and CD8+ T cells in the pancreas
that usually occurred in the absence of Treg cells was inhibited
(Figure 6B). The induction of Th17 effector cytokines was atten-
uated even more, suggesting that they might be a downstream
event (Figure 6C). Importantly, the diabetes normally triggered
by Treg cell ablation was strongly inhibited by IFN-g blockade,
being both delayed and less frequent (Figure 6D).
Lastly, we sought to establish a role for NK cells themselves in
unleashing Teff cell activities. Treatment with reagents specific
for asialo-Gm1 or NKp46 did not lead to effective NK-cell deple-
tion. Therefore, we introduced the NK1.1 marker into the
BDC2.5/NOD.Fox3DTR line by crossing it with a NOD.NK1.1 con-
genic line (Carnaud et al., 2001). As expected, ablation of Treg
cells from the F1 mice by DT treatment for 24 hr resulted in an
augmented population of NK cells, which was substantially
depleted by coadministration of anti-NK1.1 (Figure 7A). Therewere accompanying reductions in the expression of the genes
encoding both IFN-g and granzyme-B by pancreatic CD4+
T cells (Figure 7B), reductions that correlated nicely with the
loss of NK cells (Figure 7C). In contrast, the expression of gran-
zyme B by the remaining NK cells was unaltered (Figure 7B),
arguing for its independence of NK-cell-produced mediators
(notably IFN-g).
DISCUSSION
This study addressed where and how Treg cells impact on auto-
immunity, in particular the autoimmune attack on the pancreatic
islets that preludes T1D. We chose a punctual loss-of-function
approach that permitted specific, controlled elimination of Treg
cells in prediabetic BDC2.5/NODmice with an ongoing, but con-
tained, insulitis. Acute Treg cell ablation had a devastating effect
in this context: within hours, the ‘‘well-behaved’’ leukocytes
within the insulitic lesion were unleashed, culminating in armed
effector cells that rapidly executed terminal destruction of the
mass of islet b cells. The strength and synchrony of this response
facilitated dissection of the intervening molecular and cellular
events. The earliest and most striking changes subsequent to
Treg cell depletion were observed within the infiltrated islets
rather than in the allied lymphoid tissue. An activated, expanding
population of NK cells drove an early increase in the production
of IFN-g, which had a dominant impact on the gene-expressionImmunity 31, 654–664, October 16, 2009 ª2009 Elsevier Inc. 659
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Treg Cell Control of an Insulitic Lesionprogram of CD4+ T effector cells and ultimately provoked the
development of clinical diabetes.
It may be instructive, first of all, to consider these findings in
the context of previously reported experiments entailing punc-
tual ablation of Treg cells. Inserting a DTR-encoding construct
into the endogenous Foxp3 locus, which resulted in 98%
depletion of this regulatory population, the Rudensky group
found Treg cells to be required throughout life to avoid autoim-
munity in C57Bl/6 (B6) (non-autoimmunity-prone) mice: in their
absence, a devastating multiorgan autoimmune disease devel-
oped in 1 to 2 weeks (Kim et al., 2007; Lund et al., 2008). Quite
different results were published by Lahl et al. (2007), who em-
ployed a DTR-BAC strategy that resulted in only about 90%
Treg cell depletion: although B6 neonates lacking this population
developed raging autoimmunity, adults did not. Apparently, even
a small Treg cell compartment is capable of controlling this form
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Figure 5. The Loss of Treg Cell Control Trig-
gers NK Cell Activation within the Autoim-
mune Lesion
(A) Accumulation of NK cells in autoimmune
lesions. NK cells were identified as
CD19CD3CD49b+ in the lymphocyte gate. Pres-
ence of NK cells was followed in BDC2.5/NOD.
Foxp3DTR+ or DTR-negative control mice 15, 20,
24, and 48 hr after DT application in pancreas
and PLN. Upper panel: representative dot plots
are shown. Lower panel: mean and SD of four to
six independent experiments per group and time
point are presented.
(B) BrdU incorporation (as described in the legend
to Figure 2F). Upper panel shows representative
dot plots, and lower panel summarizes four to
five mice from independent experiments with
mean and SD. *Significant difference (p < 0.05).
(C) Quantitative PCR data for granzyme B (left
panel) and granzyme A (right panel) expression in
NK cells, isolated from pancreas and PLN from
BDC2.5/NOD.Foxp3DTR+ or DTR-negative litter-
mate control mice at 24 hr after DT injection. Data
are expressed as arbitrary units (AU). The mean +
SD from three to four independent experiments
are shown. *Significant difference (p < 0.05).
(D) In vivo NK cell cytotoxicity assay. DTR-positive
or DTR-negativeBDC2.5/NODmicewere depleted
of Treg cells 2 days before injection of amix of sple-
nocyte populations (CFSEloMHCI-negative targets
andCFSEhiMHCI-positive controls); 16 hr later, NK
cell activitywasmeasuredbycomparing the ratioof
the two populations in spleen, PLN, and pancreas.
Left panel, representative dot plots. Right panel
summarizes three independent experiments with
mean and SD. NK cell cytotoxicity was significantly
different in all organs (DTR+ versus DTR). Signifi-
cant difference (p = 0.0349) between PLN and
pancreas in the DTR-positive group.
of autoimmunity in adult mice. Our exper-
imental system proved to be rather like
that of Lahl et al. DT treatment of the
NOD.Foxp3DTR+ line resulted in 80%–
90% elimination of Treg cells; in 4-week-
old NOD individuals, not yet showing signs of the insulitis that
ultimately afflicts 100% of NOD mice, Treg cell depletion to
this degree led to mild leukocytic infiltrates in the lung and liver,
accompanied by strong invasion of the pancreas, but only after
12 days. Thus, the interpretation of results from our system
should not be confounded by the side-effects of devastating
systemic autoimmunity. Another point to keep in mind is that
autoimmunity is already installed in our system, based on predi-
abetic BDC2.5/NOD mice, so that a lymph node priming event
triggered by the loss of Treg cells is not a requirement for disease
to initiate. This is most likely the reason why we saw autoimmune
manifestations already within hours, rather than in the several
days reported for the B6 systems (Kim et al., 2007; Lund et al.,
2008).
A key, somewhat unexpected finding was the early activation
of NK cells after Treg cell depletion, resulting in their expansion,
660 Immunity 31, 654–664, October 16, 2009 ª2009 Elsevier Inc.
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Figure 6. IFN-g Drives the Autoimmune Response Provoked by Treg Cell Removal
(A–C) BDC2.5/NOD.Foxp3DTR+ or DTR-negative control mice were treated with DT and injected with anti-IFN-g or control rat Ig (0.5 mg). Cells were isolated 24 hr
after treatment from pancreas and PLN. (A) Decreased NK cell accumulation in anti-IFN-g-treated group. Summary of four mice per group and organ with mean
and SD is shown. *Significant difference (p < 0.05). (B) Quantitative PCR data from NK, CD4+ and CD8+ cell for IFN-g expression. Data are expressed as arbitrary
units (AU); one representative experiment out of two is shown. (C) Quantitative PCR data for IL-17, IL-21, and IL-22 from CD4+ T cells isolated from pancreas and
PLN. Data are expressed as arbitrary units (AU), and one representative experiment out of two is shown.
(D) Diabetes incidence of BDC2.5/NOD.Foxp3DTR+ and DTR control animals after DT treatment as described in Experimental Procedures. Foxp3DTR+ group was
split into anti-IFN-g or control rat Ig (1 mg) treated set. Seven to eight mice per group and treatment are displayed. p value was calculated with log-rank test for
survival curves. Arrows indicate days of antibody injection.a burst of IFN-g production as rapidly as 15 hr later, and subse-
quent expression of effector molecules such as granzymes A
and B. Teff cells responded very rapidly to the increase in
IFN-g, and their ultimate destructiveness toward islet b-cells de-
pended on it. It is not yet known towhat extent b-cell deathmight
also depend on the direct killing function of NK cells, perhaps via
granzyme activity. While NK cells have recently been reported to
control the destructiveness of insulitis in a few particularly
aggressive models of autoimmune diabetes (Poirot et al., 2004;
Alba et al., 2008), there has been little hint that their behavior is
kept in check so immediately and powerfully by Treg cells.
That NK cells can be subjugated by Treg cell control has been
reported in other contexts. They become activated and/or
expand inmice constitutively or punctually depleted of Treg cells
(Kim et al., 2007; Terme et al., 2008; Ghiringhelli et al., 2005; Lund
et al., 2008), and Treg cells can augment various of their in vivo
activities, for example, their proliferation, cytotoxicity, NKG2D
receptor expression, and ability to control tumor growth. How-
ever, in all of these previous studies, the secondary lymphoid
organs were the focus of attention, and NK cells were thought
to join the action rather late, subsequent to, and dependent on
critical interactions between DCs and CD4+ Teff cells (Kim
et al., 2007; Terme et al., 2008). The early involvement of NK cells
in the diabetogenic process provoked by Treg cell depletion in
the BDC2.5/NOD systemmost likely reflects their prerecruitment
to the insulitic lesion and at least partial activation therein. It is not
yet clear whether the Treg cells act directly on NK cells to
dampen IFN-g production, as they have been seen to do
in vitro in a different disease setting (Ghiringhelli et al., 2005).
Alternatively, they might operate through the intermediary of
DCs, perhaps keeping in check an IL-12-IFN-g feed-forward
loop, reminiscent of what is being observed in more and more
experimental settings (Martin-Fontecha et al., 2004; Wu et al.,2007). Indeed, our most recent studies on even earlier time
points after Treg cell ablation (illustrated in Figure S4) revealed
induction of the Ifng gene in pancreatic NK cells already at 7 hr
after DT treatment, followed shortly thereafter (12 hr) by an
increase in DC expression of the Il12b gene. Anti-IL-12p40 treat-
ment reduced, though did not extinguish, Ifng gene expression
by NK cells, but did not influence granzyme B expression over
the same time-frame.
Thus, Treg cell control of IFN-g production, and thereby
effector cell activities directly within infiltrated islets of BDC2.5/
NOD mice, seems to be an important element of their prolonged
restraint of the progression of insulitis to overt diabetes. This
conclusion does not mean, however, that in the setting of unma-
nipulatedmice, BDC2.5, or other, the long-delayed spontaneous
emergence of effector cells from Treg cell control and develop-
ment of diabetes necessarily requires IFN-g. Indeed, NOD
mice show only mild disease attenuation in the absence of
IFN-g or IFNg-R (Hultgren et al., 1996; Kanagawa et al., 2000;
Serreze et al., 2000), although, on the other hand, injection of
an anti-IFN-g was found to have a strong effect (Debray-Sachs
et al., 1991), T-bet is a requirement (Esensten et al., 2009), and
IFN-g-producing Th1 cells potently induce disease on transfer
(Katz et al., 1995). It may be that Treg cell control of IFN-g
production keeps the autoimmune lesion in check for a pro-
tracted period (and in its absence diabetes is immediate and
intense), but that with time, effector cells bypass this restraint
and proceed to decimate the b cells by an IFN-g-independent
mechanism. An obvious possibility would be through the slow
emergence of a Th17 or similarly autoaggressive population.
The emergent population might be less effectively controlled
by Treg cells, so such a switch could explain observations of
a reduced susceptibility of CD4+ Teff cells to Treg cell suppres-
sion in aging NOD mice as they develop clinical diabetes (YouImmunity 31, 654–664, October 16, 2009 ª2009 Elsevier Inc. 661
Immunity
Treg Cell Control of an Insulitic Lesionet al., 2005; Gregori et al., 2003). Moreover, it is possible that any
such alternative CD4+ Teff cell population might expand in the
long-term, but not acute, absence of IFN-g, thus explaining the
discrepancies mentioned above.
Treg-cell-based therapy is currently seen as an attractive
strategy for preventing or halting the progression of T1D, as
well as multiple other autoimmune disorders. For such an
approach to be optimally successful, it will be highly advanta-
geous to know precisely where and how Treg cells are exerting
their impact, which may well vary in different disease settings.
EXPERIMENTAL PROCEDURES
Mice
Mice expressing the human DTR under the control of foxp3 transcriptional
control elements (Foxp3DTR) were generated by BAC transgenesis. The BAC
construct spanned from 150 kb upstream to 70 kb downstream of the
Foxp3 transcription start-site. A DTR-eGFP cDNA with a stop codon was in-
serted between the first and second codons of the Foxp3 open reading frame.
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Figure 7. NK Cells Directly Influence CD4+ T Cell Activation after
Treg Cell Removal
BDC2.5/NOD.Foxp3DTR line was crossed with NK1.1-congenic NOD mice,
and anti-NK1.1 (0.5 mg) was injected to efficiently deplete NK cells in
NK1.1+ offspring. Data shown are derived from the pancreas.
(A) Accumulation of NK cells in the autoimmune lesion and NK cell depletion
efficiency. The presence of NK cells was followed in BDC2.5/NOD.Foxp3DTR+
or DTR-negative control mice 24 hr after DT application in pancreas; anti-
NK1.1 represents the anti-NK1.1-treated group, and crtl represents control
group. Left panel: representative dot plots are shown. Right panel: mean +
SD of four to five mice per group are presented.
(B) Quantitative PCR data from CD4+ and NK cells for IFN-g and granzyme
B (Gzmb) expression isolated from the pancreas and described in (A). Each
dot represents an individual mouse.
(C) Quantitative PCR data from CD4+ cell for IFN-g and granzyme B (Gzmb)
expression are plotted against the percentage of NK cells in the pancreas.
p values and R2 were calculated. Each dot represents an individual mouse.662 Immunity 31, 654–664, October 16, 2009 ª2009 Elsevier Inc.The recombinant Foxp3-DTR-eGFP BAC was injected into NOD fertilized
oocytes, and offspring were genotyped by PCR.
NOD-LtDOI (NOD), NOD.Foxp3DTR, and BDC2.5/NOD TCR transgenic mice
(Katz et al., 1993) were bred in the specific-pathogen-free facility of the Joslin
Diabetes Center. Four-week-old NOD and 4- to 6-week-old female BDC2.5/
NOD.Foxp3DTR+ mice and BAC-negative control animals were i.p. injected
with DT (Sigma, St. Louis, MO) (40 ng/g body weight) and were analyzed at
the indicated time points.
For NK cell depletion, the BDC2.5/NOD.Foxp3DTR line was crossed with the
NK1.1-congenic NOD line (Carnaud et al., 2001). NK cell depletion was per-
formed by i.p. injection of the depleting mAb against NK1.1 (clone, PK136;
0.5 mg) 1 day before the injection of DT. B2m-deficient NOD mice were
used as splenocyte donors in the in vivo NK cytotoxicity assay. IFN-g was
blocked by i.p. injecting anti-IFN-gmAb (clone, R4-6A2) control rat Ig together
with the first injection of DT. Mice received a second injection of anti-IFN-g
mAb on day 2. IL-12p40 was blocked by i.p. injection of mAb against
IL-12p40 (clone, C17.8; 0.5mg) together with the injection of DT. Animal exper-
iments were conducted under protocols approved by the Institutional Animal
Care and Use Committees of the Joslin Diabetes Center and Harvard Medical
School.
Disease Assays
For histology, the pancreas was excised at different time points after DT injec-
tion and was fixed in formalin, and stepped five-micron sections were stained
with H&E. For diabetes incidence studies, mice were DT injected on days 0, 1,
3, and 5 (or until diabetes developed, but not longer than 5 days), and diabetes
was assessed by measuring blood-glucose levels (350 mg/dl on two consec-
utive draws).
Cell Sorting and Flow Cytometry
Different leukocyte subsets were isolated from the spleen, PLN, and pancreas
at the indicated time points after Treg cell depletion, and the cells were stained
with the stated mAbs. In some experiments, leukocytes were sorted directly
into Trizol using the Moflo instrument. Isolated RNA was used for quantitative
PCR or microarrays.
Cell-surface and intracellular stainings were performed with mAbs against
CD3 (clone 145-2C11, BD), CD4 (clone RM4-5, BioLegend), CD8 (clone
5H10; BD), CD19 (clone 6D5; Invitrogen), CD49b (clone HMa2; BD), CD25
(clone PC61; eBioscience), CD69 (clone H1.2F3; BD), Foxp3 (clone FJK-16
s; eBioscience), IFNg (clone XMG1.2; BD), TNF-a (clone MP6-XP22; BD),
IL-2 (clone JES6-5H4; BD), IL-4 (clone 11B11; BD), IL-17 (clone TC11-
18H10; BD), or IL-10 (clone JES5-16E3; BD). Foxp3 staining was performed
according to the manufacturer’s instructions (eBiosciences). For intracellular
cytokine staining, cells were stimulated with PMA (50 ng/ml) (Sigma) and ion-
omycin (1 nM) (Calbiochem) for 4 hr. Golgistop (BD) was added to the culture in
the recommended amount during the last 3 hr, followed by fixing and perme-
abilization according to the manufacturer’s instructions (BD). In vivo NK cell
cytotoxicity assay: Treg cells were depleted in BDC2.5/NOD.Foxp3DTR+
mice by DT 2 days before 1 3 107 CFSE-labeled target cell were i.v. injected.
Target cells were a mix of splenocyte populations (CFSElo MHCI-negative
targets [B2m-deficient NOD cells] and CFSEhi MHCI-positive controls [WT
NOD cells]); 16 hr later, NK-cell-kill activity was measured in different organs
by comparing the ratio of the two populations in reference to the input mix.
For BrdU staining, BrdU (1mg, Sigma) was i.v. injected 48 hr after DT admin-
istration, and the mice were sacrificed 1 hr later. The pancreas and PLN were
removed and digested for about 15 min with collagenase type IV (1 mg/ml;
Sigma) and DNase (0.5 mg/ml; Sigma). Cells were fixed and permeabilized
according to the manufacturer’s instructions (BD) for BrdU staining and were
then analyzed using the LSRII instrument and FlowJo software.
Microarrays
RNA was prepared from sorted CD4+ T cell populations from BDC2.5/NOD.
Foxp3DTR+ mice using Trizol as described (Yamagata et al., 2004). RNA was
amplified for two rounds (MessageAmp aRNA, Ambion), biotin-labeled (BioAr-
ray High Yield RNA Transcription Labeling, Enzo), and purified using the
RNeasy Mini Kit (QIAGEN). The resulting cRNAs were hybridized to M430
2.0 chips (Affymetrix). All of the cell populations analyzed were generated in
duplicate or triplicate. Raw data were normalized using the RMA algorithm
Immunity
Treg Cell Control of an Insulitic Lesionimplemented in the ‘‘Expression File Creator’’ module from the GenePattern
software package (Reich et al., 2006). Data were visualized using the ‘‘Multi-
plot’’ modules from GenePattern.
ACCESSION NUMBERS
Datasets have been deposited at NCBI-GEO under accession no. GSE18136.
SUPPLEMENTAL DATA
Supplemental Data include one table and four figures and can be found
with this article online at http://www.cell.com/immunity/supplemental/
S1074-7613(09)00411-7.
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